Pieris Pharmaceuticals ([[PIRS]] -1.4%) enters into a license and transfer agreement with Enumeral Biomedical ([[ENUM]] +16.6%) for a non-exclusive global
Pieris Pharmaceuticals (PIRS) is developing the Anticalin® class of biotherapeutic compounds, for which they have exclusive worldwide rights. The company is increasingly focusing on the application of Anticalins® in immunooncology (IO), as the natural strengths of the platform are well-suited to tha ...
Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today ...
Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including ...
BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date on all of the industry's business, science and regulatory news -- mergers and collaborations, FDA hearings and results, breakthroughs in resear ...
iTechDachs
: Der Deal ist im Detail m.E. noch besser
mit bis zu 1,8 Milliarden Dollar für Meilensteine (minimal 5- maximal 8 Projekte) und zusätzlich bis zu zweistelliger Umsatzbeteiligung sowie bis zu 4x vollständige US-Vertriebsrechte ist es ein Knüller für eine 40 Personenfirma. Die 30 Millionen Vorabzahlung entsprachen alleine schon 50% der Marktkapitalisierung von rund 60 Millionen US-Dollar vor dem Deal.
Thread abonnieren
